Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;13:965100. doi: 10.3389/fgene.2022.965100

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Zhu and Wang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

To verify the expression of HSP90B1 in bladder urothelial carcinoma (BLCA) and its prognostic significance. (A) The expression of HSP90B1 protein in BLCA was detected using immunohistochemistry. (B) HSP90B1 protein was expressed in paired samples of BLCA. (C) HSP90B1 protein was expressed in unmatched samples of BLCA. D, (E) Prognostic difference and receiver operating characteristic curve of overall survival in BLCA between the HSP90B1 high expression group and HSP90B1 low expression group. (F) Difference analysis of survival and death rate between the high and low HSP90B1 expression groups in patients with BLCA. (G) Analysis of the difference in survival time between the HSP90B1 high expression group and HSP90B1 low expression group in patients with BLCA. (H, J) Univariate and multivariate cox regression analyses of HSP90B1 and pathological parameters on the prognosis of BLCA. (I, K) Nomograms and calibration curves were drawn to predict the impact of HSP90B1 and tumour size on the 2, 4 and 6-years prognosis of patients with BLCA.